ES3012120T3 - Treatment of cholestatic pruritus with seladelpar - Google Patents

Treatment of cholestatic pruritus with seladelpar Download PDF

Info

Publication number
ES3012120T3
ES3012120T3 ES21201888T ES21201888T ES3012120T3 ES 3012120 T3 ES3012120 T3 ES 3012120T3 ES 21201888 T ES21201888 T ES 21201888T ES 21201888 T ES21201888 T ES 21201888T ES 3012120 T3 ES3012120 T3 ES 3012120T3
Authority
ES
Spain
Prior art keywords
day
seladelpar
compound
pruritus
cholestatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21201888T
Other languages
English (en)
Spanish (es)
Inventor
Pol Boudes
Charles A Mcwherter
Alexandra S Steinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Application granted granted Critical
Publication of ES3012120T3 publication Critical patent/ES3012120T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ladders (AREA)
ES21201888T 2017-09-26 2018-09-24 Treatment of cholestatic pruritus with seladelpar Active ES3012120T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26

Publications (1)

Publication Number Publication Date
ES3012120T3 true ES3012120T3 (en) 2025-04-08

Family

ID=64564950

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21201888T Active ES3012120T3 (en) 2017-09-26 2018-09-24 Treatment of cholestatic pruritus with seladelpar
ES18811954T Active ES2902349T3 (es) 2017-09-26 2018-09-24 Tratamiento de prurito colestásico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18811954T Active ES2902349T3 (es) 2017-09-26 2018-09-24 Tratamiento de prurito colestásico

Country Status (26)

Country Link
US (2) US20190105291A1 (enExample)
EP (3) EP3973959B8 (enExample)
JP (1) JP7023371B2 (enExample)
KR (1) KR102376794B1 (enExample)
CN (1) CN111132675B (enExample)
AU (2) AU2018342323B2 (enExample)
BR (1) BR112020005074A2 (enExample)
CA (1) CA3076614C (enExample)
CY (1) CY1124894T1 (enExample)
DK (1) DK3973959T3 (enExample)
ES (2) ES3012120T3 (enExample)
FI (1) FI3973959T3 (enExample)
HR (2) HRP20250022T1 (enExample)
HU (2) HUE057377T2 (enExample)
IL (2) IL273569B (enExample)
LT (2) LT3973959T (enExample)
MX (1) MX392537B (enExample)
PL (2) PL3687523T3 (enExample)
PT (2) PT3973959T (enExample)
RS (1) RS62790B1 (enExample)
SG (1) SG11202002253SA (enExample)
SI (2) SI3687523T1 (enExample)
SM (1) SMT202200171T1 (enExample)
UA (1) UA125600C2 (enExample)
WO (1) WO2019067373A1 (enExample)
ZA (1) ZA202001646B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR20220140762A (ko) * 2020-02-10 2022-10-18 장피트 엘라피브라노에 의한 원발 담즙성 담관염의 치료
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
HUE066653T2 (hu) 2021-02-01 2024-08-28 Cymabay Therapeutics Inc Cholangiopathiák kezelése seladelparral
EP4654957A1 (en) 2023-01-29 2025-12-03 CymaBay Therapeutics, Inc. Treatment of uremic pruritus
KR20250139304A (ko) 2023-01-29 2025-09-23 사이머베이 쎄라퓨틱스, 인코퍼레이티드 만성 소양증 피부병의 치료

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PL3119384T3 (pl) * 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US20200276178A1 (en) * 2017-09-13 2020-09-03 Novartis Ag Combinations comprising fxr agonists

Also Published As

Publication number Publication date
CY1124894T1 (el) 2023-01-05
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (enExample) 2022-02-14
CN111132675B (zh) 2023-04-25
EP3973959A1 (en) 2022-03-30
EP3973959B1 (en) 2024-12-11
US20210283078A1 (en) 2021-09-16
JP2020535225A (ja) 2020-12-03
LT3687523T (lt) 2022-03-25
IL288340A (en) 2022-01-01
ZA202001646B (en) 2021-08-25
US20190105291A1 (en) 2019-04-11
JP7023371B2 (ja) 2022-02-21
PT3687523T (pt) 2021-12-06
SI3973959T1 (sl) 2025-03-31
WO2019067373A1 (en) 2019-04-04
IL288340B1 (en) 2023-01-01
EP3973959B8 (en) 2025-01-15
KR20200058458A (ko) 2020-05-27
HUE057377T2 (hu) 2022-05-28
RU2020114644A (ru) 2021-10-27
IL273569B (en) 2021-12-01
SI3687523T1 (sl) 2022-05-31
PL3973959T3 (pl) 2025-03-24
CA3076614A1 (en) 2019-04-04
BR112020005074A2 (pt) 2020-09-15
AU2021254641B2 (en) 2022-02-24
LT3973959T (lt) 2025-01-10
AU2021254641A1 (en) 2021-11-18
CA3076614C (en) 2023-02-07
UA125600C2 (uk) 2022-04-27
IL288340B2 (en) 2023-05-01
IL273569A (en) 2020-05-31
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
EP3687523A1 (en) 2020-08-05
MX2020007273A (es) 2022-05-23
MX392537B (es) 2025-03-04
PL3687523T3 (pl) 2022-02-21
AU2018342323A1 (en) 2020-04-16
SMT202200171T1 (it) 2022-05-12
PT3973959T (pt) 2025-01-24
EP3687523B1 (en) 2021-11-03
AU2018342323B2 (en) 2021-09-23
NZ762976A (en) 2021-11-26
HRP20212010T1 (hr) 2022-04-01
EP4523744A3 (en) 2025-06-04
RS62790B1 (sr) 2022-02-28
FI3973959T3 (fi) 2025-02-03
CN111132675A (zh) 2020-05-08
SG11202002253SA (en) 2020-04-29
HUE070033T2 (hu) 2025-05-28
ES2902349T3 (es) 2022-03-28
DK3973959T3 (da) 2025-01-20

Similar Documents

Publication Publication Date Title
ES3012120T3 (en) Treatment of cholestatic pruritus with seladelpar
ES2701094T3 (es) Tratamiento de enfermedades colestáticas intrahepáticas
US11224580B2 (en) Treatment of intrahepatic cholestatic diseases
KR102408288B1 (ko) 간내 담즙 정체성 질환의 치료
RU2781281C2 (ru) Лечение холестатического зуда
HK40121699A (en) Treatment of cholestatic pruritus
HK40062783B (en) Treatment of cholestatic pruritus with seladelpar
HK40062783A (en) Treatment of cholestatic pruritus with seladelpar
HK40033446A (en) Treatment of cholestatic pruritus with seladelpar
HK40033446B (en) Treatment of cholestatic pruritus with seladelpar
NZ762976B2 (en) Treatment of cholestatic pruritus
JP7596548B2 (ja) 胆管症の治療
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases